Pharmaceutical Tin Can Making Machine: GMP-Compliant Container Production & FDA/EU Regulation

# Pharmaceutical Tin Can Making Machine: GMP-Compliant Equipment for Drug-Grade Metal Packaging

**Key Takeaways:**

– The global pharmaceutical packaging market reached **USD 178.07 billion** in 2025, projected to grow to **USD 399.71 billion** by 2034 at a **CAGR of 9.4%**, according to **Straits Research 2025**.
– Pharmaceutical tin cans require five distinct engineering adaptations compared to standard industrial containers: GMP-compliant cleanroom compatibility, USP/Ph.Eur.-grade internal coatings, tamper-evident sealing systems, full serialization traceability, and documentation packages for IQ/OQ/PQ validation protocols.
– India’s pharmaceutical packaging market alone grew from **USD 5.14 billion** (2025) to a projected **USD 8.18 billion** by 2031 at **8.05% CAGR**, per **Mordor Intelligence**, reflecting the scale of equipment demand emerging from South and Southeast Asian pharma manufacturing hubs.
– China’s pharmaceutical packaging sector, valued at **USD 22.96 billion** in 2025, represents the single largest Asia-Pacific market — a direct driver of demand for tin can making machines that meet both NMPA domestic standards and export-market FDA/EU GMP requirements.

—

## Introduction: Why Pharmaceutical Tin Cans Demand a Different Class of Machine

Metal packaging has served the pharmaceutical industry for decades — from ointment tins and powder cans to tablet containers and diagnostic kit housings. But manufacturing tin cans for pharmaceutical products is not an extension of standard food-can or paint-can production. The regulatory environment, contamination tolerance thresholds, and traceability requirements create a fundamentally different engineering challenge.

According to **Mordor Intelligence’s 2026 report**, the global pharmaceutical packaging market was valued at approximately **USD 154.78 billion** in 2025 and is forecast to reach **USD 218.81 billion** by 2031 at a **CAGR of 5.94%**. Within this market, metal containers — particularly tinplate and tin-free steel cans — occupy a specialized segment serving oral solid dosage forms (tablets, capsules), topical preparations (ointments, creams), powders, and certain liquid formulations where light-blocking and hermetic sealing properties are essential.

The equipment used to produce these containers must satisfy requirements that go far beyond dimensional accuracy and production speed. Every contact surface, every lubricant residue, every particle emission from a forming die must meet standards that would be excessive for food packaging but are non-negotiable for pharmaceutical applications governed by **FDA 21 CFR Part 210/211 (cGMP)**, **EU GMP Annex 15**, and **ISO 15378**.

This guide covers the five core differentiators of pharmaceutical tin can making machines, the regulatory frameworks that shape equipment design, the market forces driving demand, and the technical specifications that procurement teams and production engineers need to evaluate.

![Small round can production line — applicable to pharmaceutical tin can manufacturing](page12_1672x1394_IM267.jpg)

—

## Table of Contents

1. [Pharmaceutical vs. Industrial Tin Can Machines: The Five Core Differences](#1-pharmaceutical-vs-industrial-tin-can-machines-the-five-core-differences)
2. [GMP-Compliant Production Environment Requirements](#2-gmp-compliant-production-environment-requirements)
3. [Pharmaceutical-Grade Internal Coating Systems](#3-pharmaceutical-grade-internal-coating-systems)
4. [Tamper-Evident Sealing and Serialization Integration](#4-tamper-evident-sealing-and-serialization-integration)
5. [Regulatory Compliance Framework: FDA, EU GMP, ICH, and WHO Standards](#5-regulatory-compliance-framework-fda-eu-gmp-ich-and-who-standards)
6. [Global Pharmaceutical Packaging Market Data and Equipment Demand](#6-global-pharmaceutical-packaging-market-data-and-equipment-demand)
7. [Equipment Specifications for Pharmaceutical Tin Can Production](#7-equipment-specifications-for-pharmaceutical-tin-can-production)
8. [Pharmaceutical vs. Chemical Tin Can Production: A Comparative Analysis](#8-pharmaceutical-vs-chemical-tin-can-production-a-comparative-analysis)
9. [Selecting the Right Machine Configuration](#9-selecting-the-right-machine-configuration)
10. [FAQ](#10-faq)

—

## 1. Pharmaceutical vs. Industrial Tin Can Machines: The Five Core Differences

Producing tin cans for pharmaceutical products requires equipment modifications at every stage — from material handling through final sealing. The following table summarizes the five areas where pharmaceutical tin can making machines diverge from standard industrial configurations.

These five differences are not optional upgrades — they are prerequisites for any pharmaceutical packaging operation that must pass regulatory audits from the **FDA**, **EMA**, **NMPA**, or **WHO Prequalification** programs.

### 1.1 The Contamination Tolerance Gap

The most fundamental difference lies in acceptable contamination levels. A paint tin can tolerating particulate residue at the parts-per-thousand level is entirely unsuitable for a pharmaceutical container where extractables and leachables must remain below thresholds established by **USP <1663>** and **<1664>**. This difference propagates through every equipment design decision: lubricant selection, die material, cleaning protocol, and even the type of compressed air used for can ejection.

### 1.2 The Documentation Burden

Industrial tin can machines ship with an operation manual and a parts list. Pharmaceutical-grade machines require a validation documentation package that includes Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) protocols — each with predefined acceptance criteria, traceable calibration certificates, and change control procedures compliant with **21 CFR Part 11** for electronic records.

—

## 2. GMP-Compliant Production Environment Requirements

### 2.1 Cleanroom Classification for Pharmaceutical Container Manufacturing

Pharmaceutical tin cans intended for direct contact with drug products must be manufactured in controlled environments. The specific cleanroom class depends on the product type and the regulatory jurisdiction, but **ISO Class 8 (equivalent to EU GMP Grade D)** is the typical minimum requirement for non-sterile pharmaceutical packaging components.

| Cleanroom Class | ISO Equivalent | Max Particles (≥0.5 μm/m³) | Typical Application |
|—|—|—|—|
| Grade A | ISO 5 | 3,520 | Sterile filling zones |
| Grade B | ISO 5 (at rest) / ISO 7 (operational) | 3,520 / 352,000 | Background for Grade A |
| Grade C | ISO 7 | 352,000 | Non-sterile aseptic processing |
| Grade D | ISO 8 | 3,520,000 | Non-sterile pharmaceutical packaging |

Equipment designed for pharmaceutical tin can production must accommodate cleanroom integration through several engineering adaptations:

– **Low-particle-emission materials**: All sliding surfaces, bearings, and drive components must use materials that do not generate particulates during normal operation. Standard carbon steel guides are replaced with hardened stainless steel or engineering polymers.
– **Clean-in-place (CIP) compatibility**: Equipment surfaces must withstand repeated cleaning with pharmaceutical-grade detergents and disinfectants without corrosion or coating degradation.
– **Sealed lubrication systems**: Open grease points are eliminated. All lubrication is contained within sealed systems to prevent aerosol contamination of the production environment.
– **HEPA-filter-compatible enclosures**: Machine housings are designed to interface with overhead HEPA filtration systems, maintaining positive pressure differentials.

### 2.2 Equipment Design for Contamination Prevention

**ISO 15378** — the quality management standard for primary pharmaceutical packaging materials — builds upon ISO 9001 with GMP-specific requirements. For tin can making machines, this translates into specific design features:

Since **January 1, 2026**, China’s NMPA has mandated GMP compliance for all pharmaceutical packaging material manufacturers, making these design requirements obligatory for any supplier serving the Chinese pharmaceutical market.

—

## 3. Pharmaceutical-Grade Internal Coating Systems

### 3.1 Why Standard Can Coatings Are Insufficient for Pharmaceutical Applications

The internal coating of a pharmaceutical tin can serves as the primary barrier between the metal substrate and the drug product. Unlike food packaging, where coatings primarily prevent corrosion and flavor transfer, pharmaceutical coatings must prevent **extractables and leachables (E&L)** from migrating into the drug product at levels that could affect patient safety or drug efficacy.

According to **USP <661> (Plastic Packaging Systems and Their Materials of Construction)** and the analogous **Ph.Eur. 3.1 (Materials Used for the Manufacture of Containers)**, coatings must undergo rigorous testing to characterize:

– **Extractables**: Compounds that can be extracted from the coating under extreme conditions (elevated temperature, aggressive solvents)
– **Leachables**: Compounds that actually migrate into the drug product under normal storage conditions
– **Biological reactivity**: Cytotoxicity, sensitization, and irritation potential per **USP <87>** and **<88>**

### 3.2 Coating Types for Pharmaceutical Tin Cans

### 3.3 Coating Application Requirements for Pharmaceutical Grade

The coating application process on pharmaceutical tin can making machines differs from standard lines in several respects:

| Parameter | Standard Food Can Coating | Pharmaceutical Can Coating |
|—|—|—|
| Film thickness tolerance | ±10% | ±5% |
| Curing temperature control | ±10°C | ±3°C |
| Solvent residue limit | <50 mg/dm² | <5 mg/dm² | | Coating weight verification | Batch sampling | 100% inline measurement | | Cleanroom classification | Not required | ISO Class 8 minimum | The coating system must also support validation documentation — each coating batch must be traceable to its raw material lot, and the curing process must be continuously monitored with recorded temperature profiles that form part of the batch record. --- ## 4. Tamper-Evident Sealing and Serialization Integration ### 4.1 Tamper-Evident Seal Requirements Pharmaceutical packaging regulations worldwide mandate tamper-evident features on containers used for oral drug products. The **US FDA's tamper-evident packaging rule (21 CFR 211.132)** requires that certain OTC drug products be packaged in tamper-evident containers. The **EU Falsified Medicines Directive (2011/62/EU)** further extends anti-tampering requirements through anti-tampering devices on outer packaging. For tin cans used in pharmaceutical applications, tamper-evident sealing is achieved through several mechanisms: | Tamper-Evident Method | Mechanism | Application | Detection Type | |---|---|---|---| | Perforated lid | Tear strip along seam perimeter | Tablet and capsule cans | Visual — lid separates on first open | | Heat induction seal | Aluminum foil membrane bonded to can rim | Powder and ointment cans | Visual — foil must be breached | | Shrink band | PVC or PET sleeve over lid-body junction | Multi-purpose pharmaceutical cans | Visual — band must be torn | | Breakable closure | Scored lid with single-use fracture points | Diagnostic kit containers | Audible and tactile click on first open | | Child-resistant (CR) closure | Press-and-turn or squeeze-and-turn mechanism | Products requiring ISO 8317 compliance | Functional — requires specific action | ### 4.2 Serialization and Traceability Integration Modern pharmaceutical tin can making machines must accommodate serialization equipment that applies unique identifiers to each container. The regulatory frameworks driving this requirement include: | Regulation | Region | Requirement | Effective Date | |---|---|---|---| | EU FMD (2011/62/EU) | European Union | 2D DataMatrix code with unique identifier on each pack | February 2019 | | US DSCSA (Drug Supply Chain Security Act) | United States | Unit-level serialization with product identifier | November 2023 (full enforcement evolving) | | China NMPA Drug Traceability | China | Electronic supervision code for drug packaging | Ongoing rollout | | India DPCS (Drug Price Control Order) | India | Barcode and batch traceability requirements | 2025+ phased | The tin can making machine must integrate with these serialization systems through: - **Vision inspection stations**: Inline cameras verifying print quality and readability of 2D DataMatrix codes at production speed - **Rejection systems**: Automatic removal of cans with unreadable or missing codes without stopping the production line - **Data aggregation**: Linking individual container serial numbers to case-level and pallet-level codes for supply chain tracking - **Audit trail generation**: Complete electronic records of all serialization events, compliant with **21 CFR Part 11** requirements for electronic signatures and records ### 4.3 Child-Resistant Closure Integration **ISO 8317:2016** specifies requirements for child-resistant packaging for pharmaceutical products. Tin cans destined for pharmaceutical use in markets requiring child-resistant closures must integrate sealing stations capable of applying CR lids with precision that ensures: - **Opening torque within specified range**: 0.5 Nm to 2.5 Nm for adult operation, below 0.3 Nm for child attempt - **Reclosability**: The CR mechanism must function correctly after repeated opening and closing cycles (minimum 50 cycles per ISO 8317 testing protocol) - **Tamper evidence**: CR closures must incorporate a secondary tamper-indicating feature visible before the container is first opened --- ## 5. Regulatory Compliance Framework: FDA, EU GMP, ICH, and WHO Standards ### 5.1 Comprehensive Regulatory Mapping The regulatory requirements for pharmaceutical tin can making machines span multiple jurisdictions and standards. The following table provides a structured overview of the key regulations and standards that influence equipment design and operation: | Regulation/Standard | Scope | Key Requirements for Tin Can Machines | |---|---|---| | FDA 21 CFR Part 210/211 | US cGMP for drug manufacturing | Equipment design preventing contamination; cleaning validation; documentation | | FDA 21 CFR Part 11 | Electronic records and signatures | Audit trail; access controls; electronic signature validation | | EU GMP Annex 15 | Qualification and validation | IQ/OQ/PQ protocols; change management; requalification | | EU GMP Annex 1 | Sterile manufacturing | Contamination control; environmental monitoring | | ICH Q7 | GMP for active pharmaceutical ingredients | Equipment qualification; cleaning procedures | | ICH Q8 | Pharmaceutical development | Design space concept applied to packaging process | | ICH Q9 | Quality risk management | FMEA for packaging equipment failure modes | | ICH Q10 | Pharmaceutical quality system | Lifecycle management of packaging equipment | | WHO GMP | Global pharmaceutical manufacturing | Premises and equipment standards for prequalification | | ISO 15378 | Primary packaging material QMS | GMP integration with ISO 9001 for packaging manufacturers | | ISO 8317 | Child-resistant packaging | Testing requirements for reclosable pharmaceutical containers | | USP <661> / <1663> / <1664> | Container closure system testing | Extractables and leachables characterization |
| Ph.Eur. 3.1 | European pharmacopoeia materials | Materials of construction for pharmaceutical containers |

### 5.2 Validation Documentation Requirements

Pharmaceutical tin can making machines must be delivered with a comprehensive validation documentation package. The following table outlines the standard IQ/OQ/PQ structure:

| Validation Phase | Content | Acceptance Criteria Example |
|—|—|—|
| Installation Qualification (IQ) | Equipment installation verification; utility connections; calibration records; material certificates | All utilities connected per P&ID; calibration within NIST-traceable tolerances |
| Operational Qualification (OQ) | Functional testing of all machine parameters; alarm verification; safety system testing | Speed range verified at 30-40 CPM; all E-stops functional; temperature ±3°C of setpoint |
| Performance Qualification (PQ) | Production trial runs under normal operating conditions; consistency testing; coating uniformity verification | 3 consecutive production batches meeting all quality parameters; coating thickness CV ≤ 5% |

### 5.3 21 CFR Part 11 Compliance for Machine Control Systems

Modern pharmaceutical tin can making machines use PLC-based control systems with touchscreen HMIs. For FDA-regulated markets, these systems must comply with **21 CFR Part 11** requirements:

—

## 6. Global Pharmaceutical Packaging Market Data and Equipment Demand

### 6.1 Global Market Overview

The pharmaceutical packaging market represents one of the most dynamic segments in the broader packaging industry. Multiple research firms have published data confirming sustained growth driven by aging populations, biopharmaceutical expansion, and tightening regulatory requirements.

### 6.2 Regional Breakdown

### 6.3 Metal Packaging Segment within Pharmaceutical Packaging

While plastics dominate pharmaceutical packaging with **38.2%** revenue share (2025, per **Dataintelo**), metal packaging — including tinplate cans, aluminum containers, and closures — retains a critical position for specific applications:

### 6.4 Emerging Market Opportunities

The following table highlights specific emerging markets where pharmaceutical tin can making machine demand is accelerating:

| Market | Pharmaceutical Industry Development | Equipment Demand Signal |
|—|—|—|
| India | PLI scheme reimbursing capital outlays for fill-finish lines; pharma exports grew from USD 25.4B (FY23) to USD 27.8B (FY24) | GMP-compliant container manufacturing equipment for export-grade packaging |
| Southeast Asia | ASEAN pharmaceutical harmonization initiative; local manufacturing incentives in Indonesia, Vietnam, Thailand | Technology transfer partnerships for tin can production lines |
| Middle East (Saudi Arabia, UAE) | Saudi Vision 2030 healthcare localization; UAE pharmaceutical manufacturing hub development | Turnkey pharmaceutical packaging lines including tin can equipment |
| Africa | African Medicines Manufacturing Accelerator (AMMA); AU pharmaceutical manufacturing strategy | Entry-level pharmaceutical packaging equipment with validation support |
| Latin America (Brazil, Mexico) | Generic drug manufacturing expansion; ANVISA regulatory modernization | Cost-effective pharmaceutical-grade tin can lines |

—

## 7. Equipment Specifications for Pharmaceutical Tin Can Production

### 7.1 Recommended Production Line Configurations

Based on typical pharmaceutical tin can size ranges (small containers for tablets, capsules, powders, and ointments), the following production line configurations from [Yongxin Can Making Equipment](https://canmachine.org/production-line/) are suitable for pharmaceutical applications:

#### Configuration A: High-Speed Small Round Can Line (60-80 CPM)

| Parameter | Value |
|—|—|
| Production speed (CPM) | 60-80 |
| Diameter range (mm) | 60-180 |
| Sealing height (mm) | 65-320 |
| Material thickness (mm) | 0.16-0.4 |
| Total power (kW) | 12 |
| Operating voltage (V) | 380 |
| Weight (kg) | 5,300 |
| Overall dimensions (mm) | 7,600 × 1,200 × 1,900 |

This [high-speed small round can line](https://canmachine.org/) is designed for 1-5L round cans and features a modular architecture integrating six core functions. The fully automated system with PLC control and low operating noise makes it suitable for pharmaceutical cleanroom-adjacent production environments.

#### Configuration B: Standard Small Round Can Line (30-40 CPM)

| Parameter | Value |
|—|—|
| Production speed (CPM) | 30-40 |
| Diameter range (mm) | 60-180 |
| Sealing height (mm) | 66-330 |
| Material thickness (mm) | 0.16-0.4 |
| Total power (kW) | 8 |
| Operating voltage (V) | 380 |
| Weight (kg) | 2,700 |
| Overall dimensions (mm) | 5,400 × 1,200 × 1,900 |

This [standard small round can line](https://canmachine.org/production-line/) offers lower power consumption (8 kW vs. 12 kW) and a more compact footprint, making it suitable for facilities with space constraints or lower volume requirements typical of specialty pharmaceutical products.

### 7.2 Single-Machine Equipment for Pharmaceutical Applications

For pharmaceutical manufacturers producing smaller batches or requiring dedicated machines for specific can sizes, individual machines can be configured:

| Machine Type | Speed (CPM) | Size Range | Power (kW) | Weight (kg) |
|—|—|—|—|—|
| Small round can flanger (0.1-5L) | 15-18 | Ø52-180mm, H50-200mm | — | 150 |
| Small round can seamer (0.1-5L) | 15-18 | Ø52-180mm, H50-200mm | — | 750 |
| Automatic beading machine | 40-60 | Ø60-180mm, H65-320mm | 3 | 1,300 |
| Small square can flanger (1-5L) | 15-20 | 1-5L, thickness 0.2-0.3mm | 3 | 400 |
| Small square can seamer (1-5L) | 15-20 | 1-5L, thickness 0.2-0.35mm | 3 | 420 |
| Small square can beader (1-5L) | 12-17 | Diagonal 45-280mm | 2.2 | 720 |

### 7.3 Sealing Equipment Options

For pharmaceutical tin can sealing operations, multiple configurations are available depending on production volume and automation level:

| Sealer Type | Speed (CPM) | Can Diameter (mm) | Can Height (mm) | Power (kW) | Weight (kg) |
|—|—|—|—|—|—|
| Semi-automatic food can sealer | 60-80 | 52-100 | 30-124 | 1.5 | 1,500 |
| Automatic food can sealer | 40-60 | 86-116 | 30-120 | 4 | 1,800 |
| High-speed food can sealer | 200-600 | 50-100 | 55-160 | 25 | 5,300 |

### 7.4 Welding Equipment for Pharmaceutical Tin Cans

| Welder Type | Speed (can/min) | Diameter Range (mm) | Height Range (mm) | Thickness (mm) | Power (KVA) |
|—|—|—|—|—|—|
| Small can welder | 20-40 | 65-286 | 70-420 | 0.18-0.42 | 18 |
| Large can welder (fast mode) | 40-100 | 65-180 | 60-320 | 0.2-0.35 | 125 |

### 7.5 Control System Specifications for Pharmaceutical Grade

—

## 8. Pharmaceutical vs. Chemical Tin Can Production: A Comparative Analysis

Pharmaceutical tin can production shares equipment DNA with industrial chemical can manufacturing — both require metal forming, welding, flanging, and sealing. However, the pharmaceutical application introduces requirements that fundamentally change equipment specifications and operational protocols.

### 8.1 Detailed Comparison Table

### 8.2 Cross-Category Equipment Adaptation

For manufacturers transitioning from [pesticide tin can](https://canmachine.org/pesticide-tin-can-making-machine-china-2026/), [solvent tin can](https://canmachine.org/solvent-tin-can-making-machine-china-2026/), or [adhesive tin can](https://canmachine.org/adhesive-tin-can-making-machine-china-2026/) production to pharmaceutical tin cans, the following equipment modifications are typically required:

—

## 9. Selecting the Right Machine Configuration

### 9.1 Decision Framework

The selection of pharmaceutical tin can making equipment should follow a structured evaluation process:

### 9.2 Modular vs. Full-Line Configuration

For detailed production line specifications, refer to the [Yongxin production line catalog](https://canmachine.org/production-line/). For companies already operating [cosmetic tin can](https://canmachine.org/cosmetic-tin-making-machine-china-2026/) production lines, the transition to pharmaceutical-grade equipment follows a similar upgrade path as the chemical-to-pharmaceutical transition described above.

—

## 10. FAQ

### Q1: What makes a pharmaceutical tin can making machine different from a standard can making machine?

A pharmaceutical tin can making machine differs in five critical areas: cleanroom-compatible design with low-particle-emission materials, pharmaceutical-grade internal coating systems compliant with USP <661> and Ph.Eur. 3.1, tamper-evident sealing with serialization integration, full IQ/OQ/PQ validation documentation, and 21 CFR Part 11-compliant control systems. These features ensure that the cans produced meet the contamination control, traceability, and regulatory documentation requirements of pharmaceutical manufacturing environments.

### Q2: What cleanroom class is required for pharmaceutical tin can manufacturing?

The minimum cleanroom classification for non-sterile pharmaceutical tin can manufacturing is **ISO Class 8 (EU GMP Grade D)**, which allows a maximum of **3,520,000 particles ≥0.5 μm per cubic meter**. For cans used with sterile pharmaceutical products, higher classifications (ISO Class 7 or Grade C) may be required. The machine itself must be designed to operate within these environments without generating excessive particulates through low-particle-emission materials, sealed lubrication systems, and HEPA-filter-compatible enclosures.

### Q3: What is the difference between extractables and leachables in pharmaceutical tin can coatings?

**Extractables** are compounds that can be extracted from the coating material under extreme laboratory conditions using aggressive solvents and elevated temperatures — they represent the theoretical worst-case migration scenario. **Leachables** are compounds that actually migrate from the coating into the drug product under normal storage conditions over the product’s shelf life. Pharmaceutical tin can coatings must be tested for both per **USP <1663>** (extractables) and **<1664>** (leachables), with results evaluated against safety thresholds established through toxicological assessment.

### Q4: What serialization requirements apply to pharmaceutical tin cans?

Pharmaceutical tin cans require unit-level serialization for traceability. In the United States, the **Drug Supply Chain Security Act (DSCSA)** mandates a unique product identifier including a 2D DataMatrix barcode containing the National Drug Code (NDC), serial number, lot number, and expiration date. In the European Union, the **Falsified Medicines Directive (FMD)** requires similar unique identifiers. The tin can making machine must integrate inline printing systems, vision inspection cameras for code verification, and automatic rejection mechanisms for non-readable codes.

### Q5: Can a machine currently producing pesticide or solvent tin cans be upgraded for pharmaceutical use?

Partial upgrades are possible, but a complete pharmaceutical-grade conversion requires significant modifications. Key changes include replacing carbon steel contact parts with **316L stainless steel**, installing a 21 CFR Part 11-compliant control system, adding serialization integration, and implementing cleanroom-compatible enclosures. The internal coating system must be entirely replaced with pharmaceutical-grade materials. For manufacturers currently operating [pesticide tin can making machines](https://canmachine.org/pesticide-tin-can-making-machine-china-2026/) or [solvent tin can making machines](https://canmachine.org/solvent-tin-can-making-machine-china-2026/), the cost-benefit of upgrading vs. purchasing a dedicated pharmaceutical line depends on the existing machine condition and the production volume planned for pharmaceutical applications.

### Q6: What validation documentation is required with a pharmaceutical tin can making machine?

The standard validation documentation package includes three phases: **Installation Qualification (IQ)** verifying that equipment is installed correctly with all utilities connected per specifications; **Operational Qualification (OQ)** confirming that all machine functions operate within defined parameters under worst-case conditions; and **Performance Qualification (PQ)** demonstrating consistent production output meeting quality specifications over multiple production batches. Additional documentation includes calibration certificates traceable to national standards (NIST, PTB, etc.), material certificates (EN 10204 Type 3.1 for stainless steel components), and a change control procedure for any post-delivery modifications.

### Q7: What is the typical production speed for pharmaceutical tin can making machines?

Production speed depends on the can size and configuration. For small pharmaceutical round cans (60-180mm diameter), the [high-speed production line](https://canmachine.org/) achieves **60-80 cans per minute (CPM)**, while the standard line operates at **30-40 CPM**. Pharmaceutical production often runs at the lower end of these ranges to allow for inline quality monitoring, serialization verification, and tamper-evident feature application. The can body material thickness ranges from **0.16-0.4mm**, accommodating both lightweight pharmaceutical tins and heavier-gauge containers for industrial pharmaceutical products.

### Q8: What internal coating options are available for pharmaceutical tin cans?

Pharmaceutical tin can coatings include epoxy phenolic (excellent chemical resistance but contains BPA), BPA-NI (Bisphenol A Non-Intentional) formulations for markets requiring BPA-free packaging, polyester-based coatings for general pharmaceutical applications, acrylic-based coatings for heat-sensitive products, and silicone-modified coatings for ointment and cream applications requiring enhanced release properties. All coatings must meet **USP Class VI** biological reactivity testing and comply with **Ph.Eur. 3.1** materials requirements. The coating film thickness tolerance for pharmaceutical applications is **±5%**, compared to ±10% for standard food can coatings.

### Q9: What tamper-evident sealing methods are available for pharmaceutical tin cans?

Five primary tamper-evident methods are used for pharmaceutical tin cans: perforated lid with tear strip (visual indication of opening), heat induction seal with aluminum foil membrane (must be breached for access), shrink band over the lid-body junction (visual tamper evidence), breakable closure with scored fracture points (audible click on first open), and child-resistant closures compliant with **ISO 8317:2016** requiring specific press-and-turn or squeeze-and-turn actions. The choice depends on the product type, target market regulations, and whether child-resistant packaging is required for the specific drug product.

### Q10: How does 21 CFR Part 11 compliance affect the machine control system?

**21 CFR Part 11** compliance requires the machine’s PLC/HMI control system to implement: time-stamped audit trails recording every parameter change with user attribution; role-based access control separating operator, supervisor, QA, and administrator functions; electronic signatures linked to their respective electronic records; system security features including password complexity requirements and automatic timeout; automated data backup with integrity verification; and record retention capabilities meeting regulatory requirements (typically the product’s shelf life plus one year). This applies to all electronic records generated by the tin can making machine, from production parameters to maintenance logs.

### Q11: What is the market size opportunity for pharmaceutical tin can manufacturers?

The global pharmaceutical packaging market was valued at **USD 178.07 billion in 2025** and is projected to reach **USD 399.71 billion by 2034** at a **9.4% CAGR** (Straits Research). Within this market, metal packaging retains a specialized position for applications requiring light-blocking, hermetic sealing, and premium product protection. India’s pharmaceutical packaging market alone — at **USD 5.14 billion (2025)** growing to **USD 8.18 billion by 2031** — represents a significant equipment procurement opportunity, particularly as the PLI scheme drives new fill-finish line construction that requires GMP-compliant packaging equipment.

### Q12: What are the key differences between pharmaceutical and cosmetic tin can production?

While both pharmaceutical and [cosmetic tin can](https://canmachine.org/cosmetic-tin-making-machine-china-2026/) production require high-quality finishes and consistent sealing, pharmaceutical production introduces mandatory requirements absent in cosmetic applications: GMP-compliant cleanroom manufacturing environments, USP/Ph.Eur.-grade internal coatings with extractables and leachables testing, tamper-evident sealing with serialization (2D DataMatrix codes), full IQ/OQ/PQ validation documentation, and 21 CFR Part 11-compliant electronic record-keeping. Cosmetic cans may use similar base machinery, but the pharmaceutical variant requires extensive modification to meet contamination control and traceability standards.

### Q13: What power requirements do pharmaceutical tin can making machines need?

Power requirements vary by machine configuration. The [high-speed small round can line](https://canmachine.org/) (60-80 CPM) requires **12 kW** at **380V**, while the standard line (30-40 CPM) requires only **8 kW** at 380V. Individual machines such as the automatic beading machine require **3 kW**, and the small round can seamer requires between **1.5-4 kW** depending on automation level. Pharmaceutical facility planners should account for additional power needed for cleanroom HVAC systems, serialization equipment, and inline vision inspection systems.

### Q14: How long does the validation process take for pharmaceutical tin can making equipment?

The complete validation process — from IQ through PQ — typically takes **3-6 months** for pharmaceutical tin can making equipment. IQ (Installation Qualification) takes approximately 2-4 weeks covering equipment installation verification, utility connection checks, and calibration certification. OQ (Operational Qualification) requires 4-6 weeks for functional testing, alarm verification, and safety system validation. PQ (Performance Qualification) demands 6-12 weeks for production trial runs across multiple batches, consistency testing, and coating uniformity verification. The timeline extends if the facility is undergoing concurrent cleanroom qualification or if the equipment supplier is providing on-site validation support.

—

## Company Fact Declaration

Company Name	Jiujiang Yongxin Can Making Equipment Co., Ltd. (九江市永信制罐设备有限公司)
Year Established	2005
Legal Representative	Li Yingquan (李映泉)
Registered Capital	RMB 1,000,000 (fully paid)
Credit Code	91360400775882416D
Headquarters Address	No. 005 Antai Road, Automotive Industrial Park, Economic & Technological Development Zone, Jiujiang, Jiangxi, China
Core Certifications	National High-Tech Enterprise (GR202536000972); Jiangxi Province “Specialized, Refined, Differential, Innovative” Enterprise; ISO 9001 (Certificate No. 107325Q1009R0S)
Patent Portfolio	86 patents, including invention patent for Can Body and Lid Synchronized Continuous Lid Feeding Supply Device (CN118025556B, granted 2026)
Product Range	Fully automatic square can production lines (1-20L); round can production lines (0.1-25L); slitting machines; welding machines; flanging machines; seaming machines; beading machines; end-making machines; food can sealers
Key Markets	China (domestic); Thailand (3 production lines); Vietnam (2 lines); India (1 line); Saudi Arabia (1 line); plus global pharmaceutical, food, chemical, and cosmetic packaging sectors
Phone	+86-792-8268711 / +86 18970289827
Email	[email protected] / [email protected]
Website	https://canmachine.org/
About Us	https://canmachine.org/about-us/
Contact	https://canmachine.org/contact-us/

—

## References and Data Sources

– **Straits Research** (2025). Pharmaceutical Packaging Market Size, Share, Growth Analysis, 2034. Market valued at USD 178.07 billion (2025), projected USD 399.71 billion by 2034.
– **Mordor Intelligence** (2026). Pharmaceutical Packaging Market Size & Share Analysis — Growth Trends and Forecast (2026-2031). Market at USD 154.78 billion (2025), forecast USD 218.81 billion by 2031.
– **Mordor Intelligence** (2026). India Pharmaceutical Packaging Market Size and Share. Market at USD 5.14 billion (2025), forecast USD 8.18 billion by 2031.
– **Dataintelo** (2026). Pharmaceutical Packaging Products Market Research Report 2034. Market at USD 140.3 billion (2025), projected USD 242.2 billion by 2034.
– **Global Market Insights** (2026). Pharmaceutical Packaging Market Size, Share & Trends, 2035. Market at USD 172.6 billion (2025).
– **NMPA/CDE** (2026). Mandatory GMP Compliance for Pharmaceutical Packaging Material Manufacturers, effective January 1, 2026.
– **FDA 21 CFR Part 210/211**. Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs.
– **EU Directive 2011/62/EU** (Falsified Medicines Directive). Anti-tampering and serialization requirements.
– **USP <661>**, **<1663>**, **<1664>**. Container closure system testing; extractables and leachables characterization.
– **ISO 15378**. Primary packaging materials for medicinal products — Particular requirements for the application of ISO 9001:2015 with reference to GMP.
– **ISO 8317:2016**. Child-resistant packaging — Requirements for reclosable packages.
– **ICH Q7/Q8/Q9/Q10**. International Council for Harmonisation guidelines on GMP, pharmaceutical development, quality risk management, and pharmaceutical quality systems.

—

*For technical consultations on pharmaceutical tin can making machine configurations, validation documentation packages, or cleanroom-compatible equipment modifications, [contact Yongxin](https://canmachine.org/contact-us/) directly.*